On March 20, 2017 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, AZ (Press release, Myriad Genetics, MAR 20, 2017, View Source [SID1234518188]). The presentations will highlight new data on variant classification and hereditary cancer syndromes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As genetic testing for hereditary cancer syndromes increases, we are generating tremendous volumes of data and identifying new genetic variants every day. Our highest priority is making sure patients and their families get accurate test results, which demands years of variant classification experience," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "Myriad has been the leader in variant classification for more than 25 years, making us the most experienced commercial lab in the industry. Our passion for helping patients continues, and we are very excited to be presenting five new cutting-edge studies at ACMG that advance the science of variant classification."

The poster abstracts are now available here. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.

Featured Poster Presentations

Title: A significant proportion of TP53 pathogenic variants detected with a hereditary pan-cancer NGS panel are somatically acquired.
Date: Thursday, March 23, 2017: 10:00—11:30 a.m. MST.
Location: Poster 173.
Presenter: Bradford Coffee.

Title: Complexities in hereditary cancer variant classification: Three case examples.
Date: Friday, March 24, 2017: 10:30 a.m.—12:00 p.m. MST.
Location: Poster 154.
Presenter: Erin Mundt.

Title: Case report: Sub-clinical Fanconi Anemia in siblings with bi-allelic BRIP1 mutations.
Date: Friday, March 24, 2017: 10:30 a.m.—12:00 p.m. MST.
Location: Poster 378.
Presenter: Jamie Willmott.

Title: Prevalence and characterization of triplications in genes associated with hereditary cancers.
Date: Friday, March 24, 2017: 10:30 a.m.—12:00 p.m. MST.
Location: Poster 148.
Presenter: Heather LaBreche.

Title: Apparent gene conversion event detected in CHEK2 using next generation sequencing analysis.
Date: Friday, March 24, 2017: 10:30 a.m.—12:00 p.m. MST.
Location: Poster 156.
Presenter: Shujuan Pan.

On March 20, 2017 Eli Lilly and Company (NYSE: LLY) reported that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS) (Press release, Eli Lilly, MAR 20, 2017, View Source [SID1234518186]). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer who have relapsed or progressed after endocrine therapy. The results demonstrated the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in PFS, when compared to the control arm of placebo plus fulvestrant. Detailed efficacy and safety results will be presented at an upcoming medical meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about the outcome of our first Phase 3 study for abemaciclib. These data are an important milestone in our goal of bringing abemaciclib to patients with advanced breast cancer, and we look forward to our upcoming conversations with regulators," said Levi Garraway, M.D., Ph.D., senior vice president, global development and medical affairs, Lilly Oncology. "This is another example of Lilly’s commitment to delivering breakthrough treatments and improving outcomes for patients with cancer."

The global Phase 3, double-blind study was designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced (locoregionally recurrent or metastatic) breast cancer. The intent-to-treat population of 669 patients was randomized to receive abemaciclib or placebo orally twice a day on a continuous dosing schedule, given in combination with fulvestrant at its approved dose and schedule, until disease progression. Patients enrolled in the study had experienced disease progression on or within 12 months of receiving endocrine treatment in the neoadjuvant or adjuvant setting or while receiving first-line endocrine therapy for metastatic disease. Patients who had received chemotherapy in the metastatic setting were not eligible for the study.

The most common adverse events observed were diarrhea, neutropenia, nausea and fatigue, and were consistent with the previous studies of abemaciclib.

Lilly intends to submit a new drug application (NDA) for single-agent abemaciclib in the second quarter of 2017, based on the MONARCH 1 study, for the treatment of refractory metastatic breast cancer patients whose disease had progressed following multiple prior treatments, including endocrine therapy and one to two chemotherapy regimens in the metastatic setting. Lilly plans to submit an additional application for MONARCH 2 in the third quarter of this year.

Along with MONARCH 1 and MONARCH 2, Lilly currently has additional trials evaluating abemaciclib in breast cancer. MONARCH 3 is a Phase 3 trial of abemaciclib in combination with a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer. Additionally, there is a Phase 2 MONARCH trial under way: monarcHER, which is evaluating abemaciclib plus trastuzumab (with or without fulvestrant) in women with HR+, HER2+ locally advanced or metastatic breast cancer. In each of these studies, abemaciclib is administered on a continuous dosing schedule.

About Metastatic Breast Cancer
Breast cancer is the most common cancer in women worldwide with nearly 1.7 million new cases diagnosed in 2012.[1] In the U.S. this year, approximately 252,710 new cases of invasive breast cancer will be diagnosed and about 40,610 people will die from breast cancer.[2] Of all early stage breast cancer cases diagnosed in the U.S., approximately 30 percent will become metastatic, spreading to other parts of the body. In addition, an estimated six to 10 percent of all new breast cancer cases are initially diagnosed as being stage IV, or metastatic.[3] Metastatic breast cancer is considered incurable, but is generally treatable.

About Abemaciclib
In many cancers, uncontrolled cell growth arises from a loss of cell cycle regulation due to increased signaling from CDK 4 and CDK 6. Abemaciclib (LY2835219) is an investigational, oral cell cycle inhibitor, designed to block the growth of cancer cells by specifically inhibiting cyclin-dependent kinases, CDK 4 and CDK 6 and was most active against Cyclin D1 and CDK 4 in cell-free enzymatic assays. In breast cancer, Cyclin D1/CDK 4 has been shown to promote phosphorylation of the retinoblastoma protein (Rb), cell proliferation, and tumor growth. In hormone receptor-positive breast cancer cell lines, sustained target inhibition by abemaciclib reduced phosphorylation of Rb, inducing cell cycle arrest.

In 2015, the U.S. Food and Drug Administration granted abemaciclib Breakthrough Therapy Designation based on data from the breast cancer cohort expansion of the company’s Phase 1 trial, JPBA, which studied the efficacy and safety of abemaciclib in women with advanced or metastatic breast cancer. In addition to its current MONARCH clinical trials evaluating abemaciclib in breast cancer, a Phase 3 trial of abemaciclib in lung cancer is also under way.

For more information on additional abemaciclib trials, a complete listing can be found on ClinicalTrials.gov (in the search box on the home page, type in "abemaciclib").